Experimental HCV Drugs
Experimental HCV Drugs
Coverage of the 2014 International AIDS Conference
- Details
- Category: HIV Treatment
- Published on Thursday, 24 July 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.
Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.
7/25/14
TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report
- Details
- Category: HIV Treatment
- Published on Monday, 21 July 2014 00:00
- Written by HIVandHepatitis.com
The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.
Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 10 July 2014 00:00
- Written by Decision Resources Group
Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.
Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 10 July 2014 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.
Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Boehringer Ingelheim
Boehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, will withdraw pending approval requests, and will not proceed with further work in this area due to rapid changes in the hepatitis C treatment environment.
More Articles...
- European Regulators Give Positive Opinion on Daclatasvir for Hepatitis C
- AbbVie's 3D Hepatitis C Combo Gets Priority Review in U.S. and Europe
- Sofosbuvir/Ledipasvir Cures 100% of Genotype 1 Hepatitis C Patients in Japanese Study
- Daclatasvir + Asunaprevir Is Highly Effective Against Hepatitis C Genotype 1b
Web Design and Development by